New Report Examines Australia’s engagement with Global Pharma & MedTech firms

06 June 2019

Pictured: the report at the BIO International Convention's Australia Pavillion (Hall C, Booth 2349) and MTPConnect Managing Director and CEO Dr Dan Grant with St Vincents Executive Officer of Research Dr Tam Nguyen in Philadelphia.

A new report released by MTPConnect at the BIO international convention in Philadelphia highlights the role played by multinational pharmaceutical and medical technology companies in nurturing Australia’s healthtech research and commercialisation.

MTPConnect Managing Director and CEO, Dr Dan Grant, says the report was prepared in partnership with BioPacific Partners and examines the factors determining the attitudes of multinational companies engaging with Australian pharma and medtech innovators.

“Our report underscores the fact that the market for innovation is global and reaffirms the high regard that multinational pharmaceutical and medical technology firms generally have for Australia’s excellence in science and research and the quality of our regulatory system,” Dr Grant said.

“While there are some pragmatic barriers to further increasing our already strong engagement with these firms, such as Australia’s geographical isolation, the report pinpoints tangible solutions to mitigate any hurdles.

“Seeking early stage collaboration to get our innovators in front of key decision makers is important, as are focusing on areas of overlap between the multinationals and areas of excellence in Australian innovation and being at the right networking events.

“Our report is a great resource for researchers and startups and I’m pleased to join with BioPacific Partners to launch it here at BIO in Philadelphia where so many key international players have come to connect with the Australian delegation.”

Margot Bethell, Executive Director of BioPacific Partners, says the report was informed by interviews and discussions with senior players in multinational companies.

“Through close engagement with multinational firms and leveraging our experience in life science commericialisation, we’ve been able to provide a consolidated overview of the global market and the Australian industry.

“The report also explores the future of the sector including trends and drivers and how these sectors go about their external innovation,” Ms Bethell said.

“The result is a report which provides valuable insights for researchers, innovators and companies into the behaviours and attitudes of medical pharma and medtech multinationals.”

Download the report by visiting the dedicated report page.